RT Book, Section
A1 Dowell, Jonathan E.
A1 Drapkin, Benjamin J.
A1 Gerber, David E.
A1 Johnson, David H.
A2 Grippi, Michael A.
A2 Antin-Ozerkis, Danielle E.
A2 Dela Cruz, Charles S.
A2 Kotloff, Robert M.
A2 Kotton, Camille Nelson
A2 Pack, Allan I.
SR Print(0)
ID 1195013481
T1 Small Cell Lung Cancer: Diagnosis, Treatment, and Natural History
T2 Fishman’s Pulmonary Diseases and Disorders, 6e
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781260473988
LK accessmedicine.mhmedical.com/content.aspx?aid=1195013481
RD 2024/04/19
AB Small-cell  lung  cancer  (SCLC)  is,  in  many  ways,  a  unique  tumor.  Untreated,  it  is  a  highly  virulent  malignancy,  with  a  life  expectancy  best  measured  in  weeks.  Conversely,  it  displays  exquisite  chemosensitivity,  resulting  in  partial  or  complete  responses  in  the  majority  of  cases.  For  the  first  time  in  more  than  30  years,  the  standard  of  care  for  advanced  SCLC  has  changed  with  the  addition  of  immune  checkpoint  inhibitor  therapy  to  standard  chemotherapy.  Unfortunately,  even  with  this  advance,  durable  tumor  responses  are  rare,  and  as  a  result,  more  than  95%  of  SCLC  patients  die  from  their  disease.  This  chapter  reviews  the  biology,  epidemiology,  diagnosis,  clinical  presentation,  staging,  and  current  management  of  this  difficult  disease.